Published in
Elsevier, Annals of Oncology, (32), p. S1304-S1305, 2021
DOI: 10.1016/j.annonc.2021.08.2105
Links
Tools
LBA29 Nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced renal cell carcinoma: A randomized phase II trial (PRISM)
Journal article published in 2021 by
N. S. Vasudev 
,
G. Ainsworth,
S. Brown,
L. Pickering,
T. S. Waddell,
K. Fife,
R. Griffiths,
A. Sharma,
E. Katona,
H. Howard,
G. Velikova,
A. Maraveyas,
J. E. Brown,
B. Venugopal,
P. Patel
and other authors.
,
G. Ainsworth,
S. Brown,
L. Pickering,
T. S. Waddell,
K. Fife,
R. Griffiths,
A. Sharma,
E. Katona,
H. Howard,
G. Velikova,
A. Maraveyas,
J. E. Brown,
B. Venugopal,
P. Patel
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 